#NEWS: The @ec.europa.eu has granted marketing authorization for our treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). Learn more: www.boehringer-ingelheim.com/human-health... #LifeForward #PulmonaryFibrosis

#NEWS: Phase II trial initiated for our investigational triple receptor agonist for #obesity. This trial will help drive understanding of both biological and behavioural drivers of obesity to improve health outcomes. Read more 👉 go.boehringer.com/oxr1a #LifeForward

#NEWS: Full data from two Phase III trials in people living with #obesity presented at #ADA2026. These results show potential to address patients’ unmet needs in obesity and liver health. Read more 👉 go.boehringer.com/4hch #LifeForward #ADASciSessions

Lung cancers are not all the same. For some, a HER2 (ERBB2) gene mutation is what is driving it. Biomarker testing identifies what’s behind each person’s cancer, giving care teams critical information to help inform clinical decisions. Learn more: bit.ly/4nUyHXq #LifeForward #Oncology #LungCancer

#NEWS 🧪87% of pet vets say spotting hidden health problems is the most critical yet overlooked part of their job. New global findings from 1,000+ vets across 51 countries reveal what's really being missed – and why it matters for animals, food safety and public health👉 go.boehringer.com/Gy8CU

#NEWS: The CHMP of @ema.europa.eu has issued a positive opinion for our medicine in #IPF and #PPF – a major milestone in the EU review process and a step forward for people living with these serious lung diseases. Learn more: go.boehringer.com/XxUd #LifeForward #PulmonaryFibrosis

#NEWS: Our targeted therapy has received approval in China as a first-line treatment for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), making it an initial therapy option. 🧪Learn more: go.boehringer.com/_xdMW #LifeForward #Oncology #LungCancer

#NEWS: New data in NSCLC, SCLC and extrapulmonary neuroendocrine carcinoma will be presented at #ASCO26, adding to our growing body of research on targeted approaches in difficult-to-treat cancers. Learn more: go.boehringer.com/UfRlZ #LifeForward #Oncology

#NEWS: Japan’s MHWL has approved our treatment for #IPF and #PPF. Both conditions cause rapid lung-function loss, with severe quality-of-life impacts and claim many lives within just a few years of diagnosis. 🧪Learn more: go.boehringer.com/xZhV

#NEWS Today, we announced a global licensing deal w/ Immunitas Therapeutics to advance a preclinical antibody for inflammatory & autoimmune diseases. It selectively targets pathogenic immune cells at inflammation sites, w/ potential for more durable control. 🧪Learn more: go.boehringer.com/1zNK7

#NEWS: Together with Eko Health Inc., we’re launching an AI based solution to detect, visualize and grade heart murmurs in dogs. Eko Vet+™ | CANINEBEAT® AI supports veterinarians in identifying murmurs that may otherwise go unnoticed. Learn more: go.boehringer.com/6EMA5 #VetTech #LifeForward

#NEWS: Our Phase III trial in people living with #obesity or overweight without type 2 diabetes has met its co-primary endpoints. Obesity is linked to liver disease, type 2 diabetes and cardiovascular disease. Read more 👉 go.boehringer.com/Nsw9 #LifeForward

#NEWS: We’re launching a new vaccine to help prevent mastitis, one of the most common diseases in dairy cows. Designed for a two-dose administration, it offers early and long‑lasting protection. Learn more here: go.boehringer.com/m8oFO #LifeForward

Rabies is fatal once symptoms appear – but it’s preventable. Supported by our Stop Rabies program, Ecuador is accelerating efforts to eliminate dog‑mediated rabies by 2030 through vaccination, education and stronger surveillance. Read more 🧪👉 go.boehringer.com/HlQ7Y #OneHealthSummit #LifeForward

#PRESS: In 2025, we accomplished significant milestones together; we… 👉 reached more patients with our therapies than ever before 👉 invested a record EUR 6.4 bn in R&D 👉 made strong progress across Human Pharma & Animal Health with new launches and vaccines 🧪➡️ go.boehringer.com/1HN8D

#NEWS: Our global survey reveals that pet owners lack awareness of parasite risks. 43% of pet owners report parasite infections and 75% want clearer prevention advice. Read more 👉 go.boehringer.com/4yoE #vetmed #PublicHealth 🧪

#NEWS: Today, the @fda.gov approved our orally administered therapy for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment. This marks the first approved targeted therapy for this use. Learn more: go.boehringer.com/VHCH- #LifeForward

#NEWS: New Phase II trial results in primary focal segmental glomerulosclerosis (FSGS) published in The Lancet. Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure. Read more 👉 go.boehringer.com/VecpO #LifeForward

#NEWS: Advancing a promising bispecific antibody for inflammatory bowel disease This innovative approach with Simcere targets two pathways in one molecule - aiming to improve outcomes for patients living with this lifelong, progressive condition. 🧪 Learn more: go.boehringer.com/VUcXm

#NEWS: The @fda.gov has approved our new treatment for progressive pulmonary fibrosis (PPF) in adults. The approval provides hope to people living with this life-threatening condition. Learn more here: go.boehringer.com/SYRTX #LifeForward #PulmonaryFibrosis

Understanding and treating HER2driven lung cancer is a critical need. In collaboration with the @lcrf.org, we’re proud to congratulate three early career investigators, each receiving a two-year, $250K grant, to advance HER2mutated lung cancer research. Learn more here: LCRF.org/251209bi

Announcing the 2025 LCRF | Boehringer Ingelheim Early Career Investigator Awards - Lung Cancer Research Foundation

Three grants awarded for projects focused on HER2-driven lung cancer NEW YORK, NY (December 9, 2025) – The Lung Cancer Research Foundation (LCRF), in collaboration with Boehringer Ingelheim, grants tw...

lcrf.org

Lung Cancer Research Foundation@lcrf.org · 8mo ago

Announcing the 2025 LCRF | Boehringer Ingelheim Early Career Investigator Awards: three awardees each received a $250k grant for projects focused on HER2-driven lung cancer. Read more about these scientists and the focus of their studies. LCRF.org/251209bi

Dr. Adrian Krainer received the Heinrich Wieland Prize for his pioneering contributions to #RNA research, leading to the first therapy for spinal muscular atrophy (SMA). He recently visited our R&D site to share some insights. Discover our research culture: go.boehringer.com/z1-T #medsky #pharmsky

#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). 🧪 In a field where milestones are scarce, today signals meaningful momentum for the PPF community. Learn more: go.boehringer.com/ao0kp #LifeForward

#NEWS: Our investigational targeted therapy has been awarded a Commissioner’s National Priority Voucher from the U.S. FDA. Find out more here go.boehringer.com/Fyr8N #LifeForward #Oncology

#NEWS: 🧪 Building on our partnership in geographic atrophy, we’re launching a new collaboration with @cdr-life.bsky.social. Our aim is to advance antibody-based therapies for autoimmune diseases, such as lupus, multiple sclerosis and arthritis. Read more: go.boehringer.com/FOSjl

#NEWS: We’ve acquired a pre-clinical program from Kyowa Kirin to develop small molecules targeting autoimmune diseases. Our aim is to address the root cause of these conditions and deliver long-lasting therapies. 🧪 Learn more: go.boehringer.com/MPRF #Innovation #AutoimmuneDiseases #PharmSky

#NEWS: The National Medical Products Administration (NMPA) in China has approved our new treatment for idiopathic pulmonary fibrosis (#IPF). 🧪 Learn more here: go.boehringer.com/HdX1

The immune system has the remarkable ability to identify and eliminate cancer cells. Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy. Learn more 🧪: go.boehringer.com/Ki82v #LifeForward #Oncology

#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25. These advancements have the potential to fulfill patients’ unmet needs. 🧪 Find out more: go.boehringer.com/FU9K9 #LifeForward #Oncology

Living with cancer, the small, positive moments often have the biggest impact. We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys. 🧪 Discover how these moments make a difference: go.boehringer.com/YomJY #LifeForward #Oncology